| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8722869 | HPB | 2017 | 7 Pages |
Abstract
DFS does not represent an appropriate surrogate for OS in randomized trials of adjuvant therapy for resected PC. Hence, OS should remain the primary endpoint of future trials evaluating new agents in postsurgical setting.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Fausto Petrelli, Gianluca Tomasello, Michele Ghidini, Veronica Lonati, Rodolfo Passalacqua, Sandro Barni,